Opportunities and challenges of leveraging COVID-19 vaccine innovation and technologies for developing sustainable vaccine manufacturing capabilities in Africa

被引:11
|
作者
Kana, Bavesh D. [1 ]
Arbuthnot, Patrick [2 ]
Botwe, Benjamin K.
Choonara, Yahya E. [3 ,4 ]
Hassan, Fatima [9 ]
Louzir, Hechmi [10 ]
Matsoso, Precious [5 ]
Moore, Penny L. [6 ,11 ,12 ]
Muhairwe, Apollo [13 ]
Naidoo, Kubendran [2 ]
Ndomondo-Sigonda, Margareth [3 ,14 ]
Madhi, Shabir A. [7 ,8 ]
机构
[1] Univ Witwatersrand, Natl Res Fdn, Dept Sci & Innovat, Ctr Excellence Biomed TB,Fac Hlth Sci, Johannesburg, South Africa
[2] Univ Witwatersrand, South African Med Res Council Antiviral Gene Ther, Fac Hlth Sci, Johannesburg, South Africa
[3] Univ Witwatersrand, Wits Adv Drug Delivery Platform Res Unit, Dept Pharm & Pharmacol, Fac Hlth Sci, Johannesburg, South Africa
[4] Univ Witwatersrand, African Network Drugs & Diagnost Innovat Ctr Exce, Fac Hlth Sci, Johannesburg, South Africa
[5] Univ Witwatersrand, Hlth Regulatory Sci Platform, Wits Hlth Consortium, Fac Hlth Sci, Johannesburg, South Africa
[6] Univ Witwatersrand, South African Med Res Council Antibody Immun Res, Fac Hlth Sci, Johannesburg, South Africa
[7] Univ Witwatersrand, South African Med Res Council Vaccines & Infect D, Fac Hlth Sci, Johannesburg, South Africa
[8] Univ Witwatersrand, African Leadership Vaccinol Expertise, Fac Hlth Sci, Johannesburg, South Africa
[9] Univ Cape Town, Hlth Justice Initiat, Sch Publ Hlth & Family Med, Cape Town, South Africa
[10] Univ Tunis El Manar, Inst Pasteur Tunis, Lab Transmiss Control & Immunobiol Infect LR11IPT, Tunis, Tunisia
[11] Natl Inst Communicable Dis, Johannesburg, South Africa
[12] Natl Hlth Lab Serv, Johannesburg, South Africa
[13] Natl Drug Author, Kampala, Uganda
[14] African Union Dev Agcy New Partnership Africas De, Midrand, South Africa
来源
LANCET INFECTIOUS DISEASES | 2023年 / 23卷 / 08期
关键词
NEUTRALIZING ANTIBODIES; SYSTEM; VIRUS; DELIVERY; IMMUNITY; IMMUNOGENICITY; SEROTYPE-5; EFFICACY; MUCOSAL; FUTURE;
D O I
10.1016/S1473-3099(22)00878-7
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
The COVID-19 pandemic heralded unprecedented resource mobilisation and global scientific collaboration to rapidly develop effective vaccines. Regrettably, vaccine distribution has been inequitable, particularly in Africa where manufacturing capacity remains nominal. To address this, several initiatives are underway to develop and manufacture COVID-19 vaccines in Africa. Nevertheless, diminishing demand for COVID-19 vaccines, the cost competitiveness of producing goods locally, intellectual property rights issues, and complex regulatory environments among other challenges can undermine these ventures. We outline how extending COVID-19 vaccine manufacturing in Africa to include diverse products, multiple vaccine platforms, and advanced delivery systems will ensure sustainability. Possible models, including leveraging public-academic-private partnerships to enhance success of vaccine manufacturing capacity in Africa are also discussed. Intensifying research in vaccine discovery on the continent could yield vaccines that further bolster sustainability of local production, ensuring greater pandemic preparedness in resource-constrained environments, and long-term health systems security.
引用
收藏
页码:E288 / E300
页数:13
相关论文
共 50 条
  • [21] COVID-19 vaccine rollout: will it affect the rates of vaccine hesitancy in Africa?
    Ekwebelem, O. C.
    Yunusa, I.
    Onyeaka, H.
    Ekwebelem, N. C.
    Nnorom-Dike, O.
    PUBLIC HEALTH, 2021, 197 : E18 - E19
  • [22] Developing COVID-19 vaccine policy in increments
    Saag, Michael S.
    LANCET, 2021, 398 (10309): : 1382 - 1383
  • [23] Dealing with vaccine hesitancy in Africa: the prospective COVID-19 vaccine context
    Afolabi, Aanuoluwapo Adeyimika
    Ilesanmi, Olayinka Stephen
    PAN AFRICAN MEDICAL JOURNAL, 2021, 38 : 1 - 7
  • [24] Challenges to COVID-19 vaccine supply chain: Implications for sustainable development goals
    Alam, Shahriar Tanvir
    Ahmed, Sayem
    Ali, Syed Mithun
    Sarker, Sudipa
    Kabir, Golam
    ul-Islam, Asif
    INTERNATIONAL JOURNAL OF PRODUCTION ECONOMICS, 2021, 239
  • [25] Tracking a Vaccine and Developing Therapeutics for COVID-19
    Gould, Kathleen Ahern
    DIMENSIONS OF CRITICAL CARE NURSING, 2020, 39 (06) : 293 - 297
  • [26] Challenges in the Development of a Vaccine Against COVID-19
    Chen, Wei
    Zhu, Feng-Cai
    ENGINEERING, 2020, 6 (10) : 1067 - 1069
  • [27] Equal access of COVID-19 vaccine distribution in Africa: Challenges and way forward
    Aborode, Abdullahi T.
    Olofinsao, Oluwatosin A.
    Osmond, Ekwebelem
    Batubo, Abiokpoyanam P.
    Fayemiro, Omowonuola
    Sherifdeen, Onigbinde
    Muraina, Luqman
    Obadawo, Babatunde S.
    Ahmad, Shoaib
    Fajemisin, Emmanuel A.
    JOURNAL OF MEDICAL VIROLOGY, 2021, 93 (09) : 5212 - 5215
  • [28] COVID-19 vaccine decisions: considering the choices and opportunities
    Hotez, Peter J.
    Nuzhath, Tasmiah
    Callaghan, Timothy
    Colwell, Brian
    MICROBES AND INFECTION, 2021, 23 (4-5)
  • [29] Challenges and opportunities for conducting a vaccine trial during the COVID-19 pandemic in the United Kingdom
    Torok, M. Estee
    Underwood, Benjamin R.
    Toshner, Mark
    Waddington, Claire
    Sidhom, Emad
    Sharrocks, Katherine
    Bousfield, Rachel
    Summers, Charlotte
    Saunders, Caroline
    McIntyre, Zoe
    Morris, Helen
    Piper, Jo
    Calderon, Gloria
    Dennis, Sarah
    Assari, Tracy
    de Rotrou, Anita Marguerie
    Shaw, Ashley
    Bradley, John
    O'Brien, John
    Rintoul, Robert C.
    Smith, Ian
    Bullmore, Ed
    Chatterjee, Krishna
    CLINICAL TRIALS, 2021, 18 (05) : 615 - 621
  • [30] Leveraging latent assets to strengthen the COVID-19 response and vaccine roll-out in Africa
    Kaseje, Neema
    Oruenjo, Kennedy
    Kaseje, Dan
    Evans, Timothy Grant
    Tanner, Marcel
    Haines, Andy
    Nyikal, James
    BMJ GLOBAL HEALTH, 2021, 6 (05):